Challenges in Accelerating Innovative Paediatric Medicine

By Rene Pretorius

April 11, 2025

Summary

How can we advance innovative paediatric medicine and care in Europe?  Public-private collaborations like the Innovative Health Initiative (IHI) and its predecessor, the Innovative Medicines Initiative (IMI), play a key role. These initiatives have improved paediatric medicines, clinical trial infrastructures, and health solutions for children. However, challenges remain in developing paediatric medical devices and diagnostics.

 

Key Insights

  • Multi-stakeholder Collaboration: The IHI and IMI unite diverse stakeholders (industry, academia, patients, regulators) to address paediatric development challenges.
  • Clinical Trial Infrastructure: Projects like conect4children have created pan-European networks for better paediatric clinical trials.
  • Regulatory Impact: The EU Pediatric Regulation has boosted clinical trials and medicines for children, but gaps in device development persist.

 

The State of Innovative Paediatric Medicine in Europe

​The Innovative Health Initiative (IHI) and its predecessor, the Innovative Medicines Initiative (IMI), have significantly advanced pediatric research in Europe. These public-private partnerships have united academia, healthcare providers, industry, patients, regulators, and health technology assessment bodies to tackle challenges in developing pediatric medicines. Despite progress, challenges to innovation in peadiatric medicine persist, specifically:

  • Most devices are designed for adults and later adapted for children, often without robust testing in paediatric populations.

  • There is a lack of age-appropriate device sizes and functionalities, particularly for neonates and infants.

  • Few incentives exist for manufacturers to invest in paediatric-specific device innovation due to small market size, high development costs, and complex regulatory requirements.

  • Limited collaboration between engineers, clinicians, and regulators slows progress.

  • Fragmented data and insufficient clinical trial infrastructure for children further hinder development.

These gaps persist due to regulatory, economic, and technical barriers that remain unresolved.

 

The Future for Innovative Peadiatrics

To accelerate innovation in paediatric medicine, stakeholders must align early, invest in child-specific research, and streamline regulatory pathways—ensuring that safe, effective, and age-appropriate treatments reach children without delay.

  • Increased Innovation and Access: Public-private partnerships can speed up paediatric treatment development, improving outcomes and cutting costs.
  • Global Collaboration: Low patient numbers require global cooperation for sufficient data and effective treatments.
  • Policy Impact: Regulatory frameworks and incentives are vital to drive investment in pediatric research.

For more insights, check the original source here.

Reference url

Recent Posts

masitinib prostate cancer trial
        

Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study

🚀 What’s the next big thing in prostate cancer treatment?

The recent FDA and EMA authorizations for the masitinib prostate cancer trial could revolutionize care for metastatic castrate-resistant prostate cancer (mCRPC). This groundbreaking study employs a biomarker-driven strategy to optimize treatment outcomes for patients like never before!

Dive into the full article to explore the implications of this targeted therapy and how it may change the future of precision medicine in oncology.

#SyenzaNews #Oncology #PrecisionMedicine #HealthTech

BEBT-908 DLBCL treatment
        

BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhibitor in China

🚀 Are we on the brink of a revolution in DLBCL treatment?

The recent conditional approval of **BEBT-908** by China’s National Medical Products Administration is not just a milestone for oncology, but potentially a game-changer for adults battling relapsed or refractory diffuse large B-cell lymphoma. With its dual-target mechanism, this first-in-class therapy offers promising efficacy and a well-thought-out access strategy that could reshape treatment standards.

Dive into the full article to discover how BEBT-908 is setting new benchmarks in both clinical outcomes and healthcare affordability.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess

AI Cost Implications
    

AI Clinician in Pediatric ICU: A Review and HEOR Perspective

🤖 What could AI Clinician support mean for pediatric ICU care?

A new collaboration between Imperial College London and CHOC is developing an AI system to guide treatment decisions in PICUs. This article reviews the initiative and examines its broader health system implications—offering a Health Economics and Outcomes Research (HEOR) perspective on how AI may shape efficiency, equity, and value in critical care.

Read on to explore how clinical innovation intersects with healthcare economics.

#SyenzaNews #AIinHealthcare #HEOR #PediatricCare #HealthInnovation #PICU

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.